Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
RNS OUT
Malta facility up and running Mid 2022
Haha long, that did make i laff... thanks for that :)
NOTICE OF SHARE SUSPENSION
Due to a recent pilfering of Robys sandwich from the canteen fridge, all markets will suspend MGC trading until the culprit had been apprehended. Initial report have results due in 3 months so expect something about Sept next year.
Ah great thanks m8, forgot there was a loo roll change and coffee pot refill coming up.
25 October 2021 Dispatch of 2021 Annual General Meeting Documents
ASX Code: MXC
LSE Code: MXC
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) would like to advise that it has commenced distribution of the accompanying letter to shareholders, advising them of details of MGC Pharma’s 2021 Annual General Meeting (AGM) to be held on Wednesday, 24 November 2021 at 4:00pm (AWST) at 1202 Hay Street, West Perth, Western Australia 6005.
Also being dispatched to shareholders today are the Company’s Annual Report for the year ended 30 June 2021 and Notice of Annual General Meeting for the AGM.
--Ends--
Authorised for release by the Company Secretary, for further information please contact:
MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director MGC Pharmaceuticals Ltd
David Lim
Company Secretary
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.com.au info@mgcpharma.com.au
UK Broker – Turner Pope UK PR Advisors – Tavistock
Andy Thacker Charles Vivian / Tim Pearson +44 203 657 0050 +44 207 920 3150 info@turnerpope.com mgcpharma@tavistock.co.uk
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.
Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels
1
-
1
25 October 2021
LETTER TO SHAREHOLDERS – UPCOMING ANNUAL GENERAL MEETING
Dear Shareholder,
MGC Pharmaceuticals Ltd (Company) is convening an Annual General Meeting of shareholders on Wednesday, 24 November 2021 at 4:00pm (AWST) at 1202 Hay Street, West Perth, WA 6005.
The C